How to buy Cyclacel Pharmaceuticals stock | $4.32

Cyclacel Pharmaceuticals, Inc is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclacel Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around USD$150,000.

How to buy shares in Cyclacel Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Cyclacel Pharmaceuticals. Find the stock by name or ticker symbol: CYCC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cyclacel Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$4.32, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cyclacel Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Cyclacel Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cyclacel Pharmaceuticals share price

Use our graph to track the performance of CYCC stocks over time.

Cyclacel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$4.32
52-week range	USD$3.12 - USD$19.598
50-day moving average	USD$4.2094
200-day moving average	USD$4.1431
Wall St. target price	USD$21.33
PE ratio	0.2731
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.573

Buy Cyclacel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Cyclacel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cyclacel Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclacel Pharmaceuticals price performance over time

Historical closes compared with the close of $4.32 from 2020-12-11

1 week (2021-01-11)	-54.67%
1 month (2020-12-18)	2.13%
3 months (2020-10-16)	11.05%
6 months (2020-07-17)	-3.57%

1 year (2020-01-17)	440.00%
2 years (2019-01-18)	460.24%
3 years (2018-01-18)	157.14%
5 years (2016-01-15)	1,067.57%

Is Cyclacel Pharmaceuticals under- or over-valued?

Valuing Cyclacel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cyclacel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cyclacel Pharmaceuticals's P/E ratio

Cyclacel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Cyclacel Pharmaceuticals shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Cyclacel Pharmaceuticals financials

Revenue TTM	USD$150,000
Gross profit TTM	USD$-4,658,000
Return on assets TTM	-28.96%
Return on equity TTM	-41.5%
Profit margin	0%
Book value	$5.024
Market capitalisation	USD$39 million

TTM: trailing 12 months

Shorting Cyclacel Pharmaceuticals shares

There are currently 211,723 Cyclacel Pharmaceuticals shares held short by investors – that's known as Cyclacel Pharmaceuticals's "short interest". This figure is 221.7% up from 65,816 last month.

There are a few different ways that this level of interest in shorting Cyclacel Pharmaceuticals shares can be evaluated.

Cyclacel Pharmaceuticals's "short interest ratio" (SIR)

Cyclacel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Cyclacel Pharmaceuticals shares currently shorted divided by the average quantity of Cyclacel Pharmaceuticals shares traded daily (recently around 170744.35483871). Cyclacel Pharmaceuticals's SIR currently stands at 1.24. In other words for every 100,000 Cyclacel Pharmaceuticals shares traded daily on the market, roughly 1240 shares are currently held short.

However Cyclacel Pharmaceuticals's short interest can also be evaluated against the total number of Cyclacel Pharmaceuticals shares, or, against the total number of tradable Cyclacel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclacel Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cyclacel Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0439% of the tradable shares (for every 100,000 tradable Cyclacel Pharmaceuticals shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyclacel Pharmaceuticals.

Find out more about how you can short Cyclacel Pharmaceuticals stock.

Cyclacel Pharmaceuticals share dividends

We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.

Have Cyclacel Pharmaceuticals's shares ever split?

Cyclacel Pharmaceuticals's shares were split on a 1:20 basis on 15 April 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.

Cyclacel Pharmaceuticals share price volatility

Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $3.12 up to $19.598. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 1.1696. This would suggest that Cyclacel Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Frequently asked questions

• What percentage of Cyclacel Pharmaceuticals is owned by insiders or institutions?

  Currently 2.81% of Cyclacel Pharmaceuticals shares are held by insiders and 13.541% by institutions.

• How many people work for Cyclacel Pharmaceuticals?

  Latest data suggests 12 work at Cyclacel Pharmaceuticals.

• When does the fiscal year end for Cyclacel Pharmaceuticals?

  Cyclacel Pharmaceuticals's fiscal year ends in December.

• Where is Cyclacel Pharmaceuticals based?

  Cyclacel Pharmaceuticals's address is: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922

• What is Cyclacel Pharmaceuticals's ISIN number?

  Cyclacel Pharmaceuticals's international securities identification number is: US23254L6039

• What is Cyclacel Pharmaceuticals's CUSIP number?

  Cyclacel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 23254L108